Premium
Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes
Author(s) -
SOMMEIJER D. W.,
HANSEN H. R.,
VAN OERLE R.,
HAMULYAK K.,
VAN ZANTEN A. P.,
MEESTERS E.,
SPRONK H. M. H.,
TEN CATE H.
Publication year - 2006
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/j.1538-7836.2005.01763.x
Subject(s) - medicine , disease , type 2 diabetes , diabetes mellitus , pathology , bioinformatics , biology , endocrinology
Summary. Objective: To determine the relationship between abnormalities in blood coagulation and prevalent or incident cardiovascular complications in Type 2 diabetes. Design and methods: Prospective cohort study of 128 patients with Type 2 diabetes in whom blood samples were collected at baseline and after 1 year of follow‐up. All cardiovascular complications at baseline and follow‐up were recorded. Forty‐three healthy, age‐matched subjects served as a control group. Results: Logistic analysis revealed an independent relationship between soluble tissue factor (TF) and microvascular disease [per pg mL −1 TF: Exp(B) = 1.008; CI(95%)1.002–1.014], or neurogenic disease [Exp(B) = 1.006; CI(95%)1.001–1.011]. The highest levels of soluble TF were observed in patients with microvascular and neurogenic disease ( P < 0.001). Patients with Type 2 diabetes having a soluble TF concentration >300 pg mL −1 are at a 15‐fold higher risk for the presence of microvascular disease and at a 10‐fold higher risk for the presence of neurogenic disease compared with the patients with concentrations below 100 pg mL −1 . Soluble TF was correlated with tissue type plasminogen activator, von Willebrand factor antigen, systolic blood pressure and age. Levels of F1′ + 2, D‐dimer, FVIII activity, t‐PA and vWFag were not different among patients with micro‐, macro‐ or neurogenic complications compared with patients without those complications. Forty‐eight new micro‐, macro‐ and/or neurogenic complications were diagnosed after 1 year follow‐up. With the exception of higher F1 + 2 levels after 1 year all other markers remained unchanged. A trend toward higher soluble TF levels was observed in patients with new microvascular events ( P = 0.056). Conclusions: Soluble TF is associated with existing microvascular and neurogenic complications in patients with Type 2 diabetes and is a candidate marker for progression of microvascular disease.